Stay updated on Selpercatinib in RET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.

Latest updates to the Selpercatinib in RET+ NSCLC Clinical Trial page
- Check2 days agoChange DetectedA new publication reference has been added under Publications, citing a 2026 J Clin Oncol article about selpercatinib and postprogression therapies. This update enriches the study record with additional related literature tied to the trial.SummaryDifference0.0%

- Check9 days agoChange DetectedThe page’s revision label was updated from v3.5.3 to v3.5.4, reflecting a small maintenance update to the page metadata.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe study location entry for Bucharest has been updated to use an alternate spelling/formatting (removing diacritics and standardizing the text). The page also reflects an updated revision/version label.SummaryDifference0.1%

- Check67 days agoChange DetectedLocation name updated from Napoli, Campania, Italy, 80131 to Naples, Campania, Italy, 80131; page revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check81 days agoChange DetectedThe page now shows Revision: v3.4.3, replacing Revision: v3.4.2.SummaryDifference0.0%

- Check88 days agoChange DetectedIn Turkey, the study site list changed by removing Sarıyer and adding Yellowplace, both with postal code 34457.SummaryDifference0.0%

Stay in the know with updates to Selpercatinib in RET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.